News
A completely new way of delivering anti-cancer drugs
A completely new way of delivering anti-cancer drugs to tumours, using 'minicells' derived from bacteria, has been tested for the first time in humans and found to be safe, well-tolerated and even induced stable disease in patients with...
News
Novartis future growth prospects secured by industry-leading pipeline
Novartis has provided an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into commercial success to provide the basis for continued growth of the Group through 2017. Continuing...
News
Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers....
News
New drug significantly lowers bad cholesterol
For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used...
News
Results from the largest known cholesterol survey conducted in the U.S.
Results from the USAGE survey, the largest known cholesterol survey in the U.S. involving more than 10,100 statin users, were presented at the American Heart Association's Annual Scientific Sessions, the leading gathering of cardiovascular disease experts in the...
News
FDA expands use of Xarelto to treat, reduce recurrence of blood clots
The U.S. Food and Drug Administration expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment. ...
News
Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D
At its 3rd International Research & Development press conference, Boehringer Ingelheim unveiled a pipeline of unique asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer compounds that builds on the company's vast respiratory experience...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read